Japan's SoftBank plots billions in biotech investments in move that could keep the valuation flood rising — report
The valuation crazy train in biotech continues to roll into the new year with more than a dozen companies taking a chance on Nasdaq and money flowing in from all sides. Now, a Japanese institutional investor is reportedly weighing an entry into the market in a big way — will it keep the bitcoin-esque flood rising?
Already a part-time investor in biotech, SoftBank could drop billions of dollars into the industry as part of helmsman Masayoshi Son’s plan to spend around $80 billion of the firm’s own assets, according to a report from Bloomberg citing people familiar with the plan.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 148,300+ biopharma pros reading Endpoints daily — and it's free.